Metastatic colorectal cancer- third line therapy and beyond

Expert Rev Anticancer Ther. 2024 Mar 25. doi: 10.1080/14737140.2024.2334784. Online ahead of print.ABSTRACTINTRODUCTION: The outcome of patients with metastatic colorectal cancer (mCRC) has improved significantly in the last few decades. Metastatic colorectal cancer is a highly heterogenous cancer. Beyond second line chemotherapy, treatment decisions are often based on molecular testing.METHOD: In this narrative review, we provide a comprehensive summary of data from key clinical trials and discuss how to integrate these agents into the current treatment landscape of metastatic colorectal cancer.EXPERT OPINION: In the era of precision medicine, molecular testing plays an increasingly important role in the management of mCRC, Efforts need to be made to target treatment based on molecular test results.PMID:38526540 | DOI:10.1080/14737140.2024.2334784
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Authors: Source Type: research